Want to see NOTVQ full AI Analyst Report?
Top Page
Inotiv
(OTC:NOTVQ)
Select Model
Select Model
Rating:40Underperform
Price Target:
$0.01
▼(-97.96% Downside)
Action:Reiterated
Date:06/24/26
The score is driven primarily by weak financial performance—ongoing losses, highly elevated leverage, and negative free cash flow—despite some operational improvement (notably DSA momentum) noted in KPI insights. Technical indicators reinforce the risk profile, showing strong bearish momentum with the stock far below major moving averages. Valuation provides little support because earnings are negative and no dividend yield is available.
Positive Factors
End-to-end CRO capabilities
Providing integrated nonclinical and preclinical services (models, in vivo/in vitro studies, bioanalytical and pathology) creates client stickiness and higher wallet share. Over months this durable capability reduces client churn and supports repeat contracts tied to long drug development timelines.
Negative Factors
Very high leverage
Debt at roughly 5.4x equity materially limits financial flexibility, increasing refinancing and covenant risk. Elevated leverage raises interest burden and constrains the company’s ability to invest in growth or weather cyclical slowdowns over the coming months without deleveraging or external financing.
Read all positive and negative factors
Positive Factors
Negative Factors
End-to-end CRO capabilities
Providing integrated nonclinical and preclinical services (models, in vivo/in vitro studies, bioanalytical and pathology) creates client stickiness and higher wallet share. Over months this durable capability reduces client churn and supports repeat contracts tied to long drug development timelines.
Read all positive factors
Inotiv Key Performance Indicators (KPIs)
Inotiv (NOTVQ) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$418.66K
Dividend YieldN/A
Average Volume (3M)1.20M
Price to Earnings (P/E)―
Beta (1Y)1.99
Revenue Growth5.61%
EPS Growth20.77%
CountryUS
Employees1,945
SectorHealthcare
Sector Strength45
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)-2.53
Shares Outstanding34,888,145
10 Day Avg. Volume429,089
30 Day Avg. Volume1,202,902
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)0.35
Price to Sales (P/S)0.09
P/FCF Ratio-1.74
Enterprise Value/Market Cap1.15K
Enterprise Value/Revenue0.95
Enterprise Value/Gross Profit6.47
Enterprise Value/Ebitda47.32
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-2.27
Revenue Forecast (FY)$529.53M
Inotiv Business Overview & Revenue Model
Company Description
Inotiv, Inc. provides nonclinical and analytical drug discovery and development services to the pharmaceutical and medical device industries in the United States, the Netherlands, and internationally. The company operates through two segments, Dis...
How the Company Makes Money
Inotiv primarily makes money by providing outsourced research and development services and selling research-related products to life sciences customers. Key revenue streams include: (1) Service revenue from conducting preclinical/nonclinical studi...
Inotiv Financial Statement Overview
Summary
Income Statement
22
Negative
Balance Sheet
18
Very Negative
Cash Flow
15
Very Negative
| Breakdown | TTM | Sep 2025 | Sep 2024 | Sep 2023 | Dec 2022 | Sep 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 507.36M | 513.02M | 490.74M | 572.42M | 547.66M | 89.61M |
| Gross Profit | 74.60M | 65.05M | 111.17M | 165.44M | 157.21M | 30.16M |
| EBITDA | 10.20M | 24.75M | -26.76M | -26.51M | -273.42M | 15.37M |
| Net Income | -86.97M | -68.63M | -108.44M | -105.14M | -337.26M | 10.89M |
Balance Sheet | ||||||
| Total Assets | 702.42M | 771.11M | 781.36M | 856.53M | 962.90M | 321.86M |
| Cash, Cash Equivalents and Short-Term Investments | 15.18M | 21.74M | 21.43M | 35.49M | 18.52M | 138.92M |
| Total Debt | 487.77M | 503.63M | 445.12M | 417.64M | 386.49M | 174.19M |
| Total Liabilities | 625.32M | 635.09M | 610.86M | 588.04M | 603.13M | 216.73M |
| Stockholders Equity | 77.10M | 136.03M | 170.50M | 269.15M | 360.37M | 105.13M |
Cash Flow | ||||||
| Free Cash Flow | -13.61M | -27.07M | -29.11M | 380.00K | -41.52M | -1.73M |
| Operating Cash Flow | 354.00K | -10.46M | -6.80M | 27.88M | -5.22M | 10.75M |
| Investing Cash Flow | -10.26M | -12.89M | -16.83M | -28.75M | -333.72M | -54.06M |
| Financing Cash Flow | 5.63M | 23.70M | 9.68M | 15.87M | 203.15M | 198.83M |
Inotiv Technical Analysis
Negative
0.54
Price Trends
0.22
Negative
0.27
Negative
0.64
Negative
Market Momentum
-0.07
Positive
25.43
Positive
4.26
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NOTVQ, the sentiment is Negative. The current price of 0.54 is above the 20-day moving average (MA) of 0.10, above the 50-day MA of 0.22, and below the 200-day MA of 0.64, indicating a bearish trend. The MACD of -0.07 indicates Positive momentum. The RSI at 25.43 is Positive, neither overbought nor oversold. The STOCH value of 4.26 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for NOTVQ.
Inotiv Risk Analysis
Inotiv disclosed 42 risk factors in its most recent earnings report. Inotiv reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Inotiv Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
57 Neutral | $241.70M | -5.75 | -2101.40% | ― | 29.05% | 29.88% | |
55 Neutral | $41.66M | -48.45 | -6.73% | ― | 28.97% | 75.43% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | $13.08M | ― | -71.38% | ― | 0.96% | 91.13% | |
44 Neutral | $11.47M | -0.30 | 76.82% | ― | 88.49% | 21.17% | |
41 Neutral | $6.98M | -0.18 | 80.66% | ― | -13.24% | 39.65% | |
40 Underperform | $418.66K | >-0.01 | -44.77% | ― | 5.61% | 20.77% |
* Healthcare Sector Average
NOTVQ
Inotiv
0.01
-1.81
-99.34%
TRIB
Trinity Biotech
0.36
-0.29
-44.46%
VNRX
VolitionRX
1.28
-13.92
-91.58%
PRPO
Precipio
23.31
12.27
111.14%
BNGO
BioNano Genomics
1.14
-2.14
-65.24%
BDSX
Biodesix
23.34
17.70
313.83%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.